Accueil Non classé LifeVest Wearable Defibrillator For Children FDA Approved

LifeVest Wearable Defibrillator For Children FDA Approved

The LifeVest wearable defibrillator is the first and only wearable defibrillator for patients at high risk of sudden cardiac arrest (SCA). The authors noted that current guidelines do not address the routine use of WCDs such as the LifeVest® (Zoll Medical Corp., Chelmsford, MA, USA) in patients with syncope.” 1 While this is true, the authors ask us to take a common-sense approach appealing to the Bayes theorem and the pretest probability that the patient’s recurrent symptomatic events were driven by a malignant arrhythmia despite a normal echo and no significant obstructive coronary disease at catheterization.
In conclusion, in this trial, we compared the use of a wearable cardioverter-defibrillator plus guideline-directed medical therapy with guideline-directed ZOLL LifeVest Wearable Defibrillator medical therapy alone in patients who presented with an acute myocardial infarction with an ejection fraction of 35% or less.

Of note, the prescription of a wearable cardioverter-defibrillator (WCD) in this patient with syncope is not routine; indeed, although the case is well-described, it is difficult at first glance to understand what clinical features led the clinicians to prescribe the WCD.
Dr. Werner Jung, Schwarzwald-Baar Kliniken, Villingen Schwenningen, Germany, and PD Dr. Christian Veltmann, Medizinische Hochschule, Hannover, Germany, will present a symposium entitled New Onset Heart Failure Patients are Different: A Strategy for Managing SCD Risk During Medical Optimization,” Monday, 1 September, 1:00-1:45 p.m., Reykjavik, Village 6, Session #3783.

40. Unknown Noncardiac Prognosis  Setting of SCD with clear indications for secondary prevention with an ICD but in which the events around the time of SCD have created acute noncardiac issues  Anoxic brain injury  acute kidney injury  Cancer  Acute phase of recovery from an invasive procedure or surgery  When prognosis is known with certainty and the risks of nonarrhythmic death exceed those of life-threatening arrhythmia, a WCD is not indicated 40 Piccini JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death.
The Centers for Medicare and Medicaid Services guidelines stress that for patients to be considered for an implantable cardioverter-defibrillator (ICD) patients must not have had angioplasty such as a coronary artery bypass graftwithin the past three months.

15 The overall survival was not different largely because patients in the ICD group had a higher risk of non-arrhythmic death (hazard ratio 1.72; P = 0.05) suggesting that patients with risk factors for SCD are also at high risk of death from other causes.
Our results, which stem from the largest study to date among children in the United States using wearable cardioverter defibrillators, suggest that these external devices can help save the lives of children who are at the time, not good candidates for surgically implanted defibrillators because of their medical condition,” said the study’s principal investigator David Spar, M.D., assistant professor of pediatrics at the University of Cincinnati and a pediatric electrophysiologist at Cincinnati Children’s Hospital.

Charger d'autres articles liés
Charger d'autres écrits par malletsubway7
Charger d'autres écrits dans Non classé

Laisser un commentaire

Consulter aussi

Toronto Warehouse & Distribution

I have total 5 years of experience in customer order management process. I would really ap…